Scinus closes €3 million round to industrialise cell therapy
Utrecht-based biotech company Scinus has raised €3 million in fresh funding to address one of the biggest bottlenecks in modern medicine: how to manufacture advanced cell therapies at scale, safely and affordably. The capital will be used to further develop and commercialise its automated bioreactor platforms, designed to move cell treatments from artisanal lab processes to robust industrial production.
Tackling the manufacturing bottleneck in cell therapy
While breakthrough cell and gene therapies are transforming treatment for cancers, rare diseases and immune disorders, their adoption is constrained by complex, manual and costly production workflows. Each batch often has to be tailored to an individual patient, demanding strict control of cell expansion, quality and sterility.
Scinus focuses on solving this problem with closed, automated bioreactor systems that standardise and monitor cell growth in real time. By integrating advanced process control, sensors and software, the company aims to reduce variability, cut production time and lower the cost per treatment, while meeting stringent GMP and regulatory requirements.
How Scinus aims to change the cell therapy value chain
From lab-scale to industrial-scale production
The new funding will support validation of Scinus technology with pharmaceutical partners and hospital-based manufacturing units. The company plans to expand its platform for a broader range of cell types, including T cells, stem cells and other advanced therapy medicinal products (ATMPs), and to integrate enhanced data analytics for continuous process optimisation.
By enabling more reliable and scalable production, Scinus aims to accelerate clinical trials, reduce manufacturing failures and help bring next-generation cell therapies to more patients worldwide. The financing underscores growing investor interest in enabling technologies that sit behind the most advanced treatments in modern healthcare.
Positioning within Europe’s advanced therapies ecosystem
Based in Utrecht, a fast-growing hub for life sciences and biotech innovation, Scinus is part of a wider European push to build sovereign capabilities in advanced therapy manufacturing. As demand for personalised medicine rises, scalable production platforms are set to become a critical strategic asset for both healthcare systems and industry.